Latest Ratios: P/E Ratio -0.5x · EV/EBITDA 19.6x · ROE -16.0%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $24M | $283M | $712M | $844M | $580M | $551M | $221M | $162M | $272M | — |
| Enterprise Value | $268M | $526M | $938M | $1.1B | $716M | $690M | $343M | $262M | $361M | — |
| P/E Ratio → | -0.47 | — | 219.37 | 44.53 | — | — | 65.73 | — | — | — |
| P/S Ratio | 0.07 | 0.85 | 1.53 | 2.01 | 1.77 | 2.67 | 1.28 | 1.01 | 2.04 | — |
| P/B Ratio | 0.08 | 0.96 | 2.03 | 2.55 | 3.66 | 6.10 | 3.68 | 2.60 | 8.22 | — |
| P/FCF | 0.69 | 8.00 | 37.59 | — | — | — | 45.82 | 6.15 | 21.47 | — |
| P/OCF | 0.49 | 5.66 | 17.06 | 326.08 | — | — | 23.68 | 5.44 | 14.81 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.58 | 2.02 | 2.51 | 2.18 | 3.34 | 1.99 | 1.63 | 2.70 | — |
| EV / EBITDA | 19.60 | 38.45 | 14.19 | 14.32 | 14.60 | 15.44 | 7.82 | 7.09 | 17.98 | — |
| EV / EBIT | — | — | 27.46 | 19.88 | 18.50 | 18.42 | 13.29 | 20.99 | — | — |
| EV / FCF | — | 14.91 | 49.55 | — | — | — | 71.28 | 9.97 | 28.48 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 39.1% | 39.1% | 39.1% | 43.0% | 38.5% | 44.0% | 46.1% | 45.9% | 42.2% | 36.1% |
| Operating Margin | -1.1% | -1.1% | 9.6% | 12.9% | 12.1% | 18.6% | 22.7% | 20.0% | 11.8% | -0.8% |
| Net Profit Margin | -15.5% | -15.5% | 0.7% | 4.5% | -2.2% | -3.3% | 1.9% | -11.5% | -8.3% | -12.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.0% | -16.0% | 1.0% | 7.7% | -5.8% | -9.1% | 5.5% | -38.6% | -19.6% | -14.8% |
| ROA | -6.4% | -6.4% | 0.4% | 2.8% | -1.6% | -2.0% | 1.2% | -8.4% | -5.1% | -4.9% |
| ROIC | -0.5% | -0.5% | 6.0% | 9.7% | 11.4% | 14.0% | 17.0% | 16.9% | 8.6% | -0.3% |
| ROCE | -0.8% | -0.8% | 8.6% | 13.3% | 15.3% | 19.5% | 26.7% | 31.5% | 12.6% | -0.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.94 | 0.94 | 0.77 | 0.78 | 1.07 | 1.93 | 2.49 | 1.67 | 2.75 | 0.94 |
| Debt / EBITDA | 20.20 | 20.20 | 4.10 | 3.50 | 3.46 | 3.91 | 3.41 | 2.81 | 4.53 | 19.23 |
| Net Debt / Equity | — | 0.83 | 0.64 | 0.63 | 0.86 | 1.53 | 2.04 | 1.61 | 2.68 | 0.92 |
| Net Debt / EBITDA | 17.81 | 17.81 | 3.43 | 2.84 | 2.78 | 3.10 | 2.79 | 2.71 | 4.42 | 18.80 |
| Debt / FCF | — | 6.91 | 11.96 | — | — | — | 25.46 | 3.81 | 7.00 | 4.14 |
| Interest Coverage | -0.08 | -0.08 | 1.27 | 2.23 | 2.16 | 1.76 | 1.33 | 0.57 | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.91 | 0.91 | 1.24 | 1.33 | 1.34 | 1.26 | 1.26 | 0.84 | 0.72 | 1.26 |
| Quick Ratio | 0.65 | 0.65 | 0.86 | 0.86 | 0.77 | 0.88 | 1.03 | 0.61 | 0.56 | 0.81 |
| Cash Ratio | 0.10 | 0.10 | 0.17 | 0.20 | 0.17 | 0.28 | 0.43 | 0.03 | 0.02 | 0.02 |
| Asset Turnover | — | 0.44 | 0.55 | 0.51 | 0.63 | 0.52 | 0.58 | 0.66 | 0.68 | 0.39 |
| Inventory Turnover | 2.26 | 2.26 | 2.24 | 1.70 | 1.60 | 1.83 | 3.02 | 3.14 | 3.98 | 1.91 |
| Days Sales Outstanding | — | 194.66 | 169.64 | 161.26 | 142.33 | 175.08 | 164.85 | 134.87 | 144.61 | 162.33 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 0.5% | 2.2% | — | — | 1.5% | — | — | — |
| FCF Yield | 100.0% | 12.5% | 2.7% | — | — | — | 2.2% | 16.2% | 4.7% | — |
| Buyback Yield | 3.8% | 0.3% | 0.1% | 0.4% | 0.0% | 0.6% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 3.8% | 0.3% | 0.1% | 0.4% | 0.0% | 0.6% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $63M | $63M | $63M | $42M | $39M | $36M | $30M | $28M | $28M |
Includes 30+ ratios · 9 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BIOX stock.
Bioceres Crop Solutions Corp.'s current P/E ratio is -0.5x. The historical average is 55.1x.
Bioceres Crop Solutions Corp.'s current EV/EBITDA is 19.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 16.2x.
Bioceres Crop Solutions Corp.'s return on equity (ROE) is -16.0%. The historical average is -10.0%.
Based on historical data, Bioceres Crop Solutions Corp. is trading at a P/E of -0.5x. Compare with industry peers and growth rates for a complete picture.
Bioceres Crop Solutions Corp. has 39.1% gross margin and -1.1% operating margin.
Bioceres Crop Solutions Corp.'s Debt/EBITDA ratio is 20.2x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Argentine macroeconomic volatility exposure
Distressed Valuation Reflects Operational Uncertainty
Based on reported figures, the company's P/S ratio of 0.06 suggests that the market is heavily discounting future growth potential, likely due to the persistent net losses and the significant revenue contraction observed in recent quarterly filings compared to historical performance benchmarks.
The negative P/E ratio and depressed P/B of 0.07 indicate that investors are currently pricing the equity as a distressed asset rather than a growth-oriented biotechnology firm. This valuation level implies that the market remains highly skeptical of the company's ability to achieve sustainable profitability through its HB4 technology platform.
Capital Efficiency Deteriorating Amid Losses
As reported in financial statements, the ROIC has struggled to maintain positive territory, hovering near 1.4% in 2026Q2, which suggests that the company is failing to generate returns that exceed its cost of capital, a trend that warrants further investigation by fundamental analysts.
The inability to consistently compound returns on invested capital reflects the high fixed-cost burden associated with R&D and regulatory compliance. Without a clear path to margin expansion, the current capital allocation strategy appears to be eroding shareholder value rather than building a sustainable competitive moat.
Working Capital Cycles Remain Strained
According to recent SEC filings, the cash conversion cycle has expanded to 195 days in 2026Q2, indicating that the company's ability to efficiently turn inventory into cash is being hampered by the complexities of its identity-preserved supply chain and seasonal agricultural demand.
The elevated DSO and DIO figures suggest that the company is providing significant credit terms to customers or facing logistical bottlenecks in its closed-loop system. This inefficiency ties up critical liquidity, leaving the firm more exposed to the inflationary pressures inherent in its primary Argentine market.
Liquidity Buffer Nearing Critical Thresholds
Based on the 2026Q2 balance sheet, the current ratio has compressed to 0.90, falling below the critical 1.0 threshold, which implies that the company's short-term assets may no longer be sufficient to cover its immediate liabilities without significant operational or external intervention.
The decline in the quick ratio to 0.69 further highlights the company's reliance on inventory liquidation to meet short-term obligations. Investors should monitor whether the current cash reserves are sufficient to sustain operations through the next planting cycle given the ongoing cash burn.
Misapplied P/E Multiples Obscure Reality
As indicated by the provided financial data, the P/E ratio is a fundamentally flawed metric for this business model, as it fails to account for the heavy R&D capitalization and the non-cash accounting adjustments inherent in hyperinflationary reporting environments like Argentina.
Analysts should instead focus on EV/Sales or adjusted EBITDA metrics to better capture the underlying revenue-generating capacity of the biologicals and seed segments. Relying on P/E in this context ignores the significant divergence between accounting net income and the actual cash-generating potential of the HB4 technology.